The Parkinson's drug entacapone disrupts the gut microbiome by inducing iron deficiency, favoring the growth of potentially harmful bacteria like E. coli. Using advanced molecular techniques, researchers identified that entacapone interferes with iron availability, a critical resource for many gut microbes.
